[Lipodystrophic syndromes in HIV-infected patients receiving antiretroviral treatment].
Simeoni
Julia
J
Service d'Endocrinologie, Diabète et Maladie métabolique du Pr M Pinget, CHU de Strasbourg.
D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000009:adverse effects*; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects*; D005260:Female; D020022:Genetic Predisposition to Disease; D039682:HIV-Associated Lipodystrophy Syndrome / Q000139:chemically induced / Q000188:drug therapy / Q000209:etiology* / Q000503:physiopathology; D006526:Hepatitis C / Q000150:complications; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D007333:Insulin Resistance; D008297:Male; D012307:Risk Factors
D019380:Anti-HIV Agents; D007004:Hypoglycemic Agents; D000960:Hypolipidemic Agents